If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Acquisition expands high-value medical platform
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Subscribe To Our Newsletter & Stay Updated
